Heart Failure in Focus 2026: Congress in Dubai
Heart Failure in Focus 2026 took place on 20 June 2026 at Raffles Hotel Dubai. The event was organised by…
Cardiovascular Research
AllCardiovascular PharmacotherapyClinical Trials and StudiesEvidence-Based MedicineGeneral Cardiac NewsHealthcare Policy and Cardiovascular CareHeart Failure InsightsResearch
Read MoreHeart Failure in Focus 2026: Congress in Dubai
From Guidelines to Clinical Impact: GDMT Implementation
🗓️ 2026-09-10
📰 Publication: Medical Digest
Read MoreFrom Guidelines to Clinical Impact: GDMT Implementation
Managing Potassium in Patients With Heart Failure
Why potassium monitoring remains central to safe, effective heart failure treatment.
Practical Use of MRA Therapy in HFrEF
Practical clinical guidance for the considered use of MRA therapy in HFrEF.
MRA Therapy and Blood Pressure in HFrEF
Putting blood pressure into the wider context of treatment decisions in HFrEF.
MRA Therapy in Heart Failure: Understanding Endocrine Side Effects
A focused discussion of endocrine tolerability considerations in MRA therapy.
Early MRA Initiation in HFrEF: Why Timing Matters
Why timely MRA initiation deserves a place in the clinical conversation for patients with HFrEF.
When Should Heart Failure Treatment Be Down-Titrated or Stopped?
A practical reflection on when and how heart failure treatment may need to be reviewed, reduced or interrupted.
Managing HFrEF in Patients With Low Blood Pressure
Expert perspective on maintaining evidence-based HFrEF care when low blood pressure complicates treatment decisions.
Predicting Incident Heart Failure: How Well Do Risk Models Validate?
This systematic review evaluated the performance of prediction models for incident heart failure in validation studies.
Biomarker-Guided Heart Failure Management: Why Certainty of Evidence Matters
This review compared BNP or NT-proBNP-guided management with clinically guided management in heart failure, pooling randomised controlled trials.
HFpEF Pharmacotherapy: What a Network Meta-analysis Compared
This network meta-analysis compared established and emerging pharmacotherapies evaluated in randomised trials of heart failure with preserved ejection fraction (HFpEF).
Dapagliflozin Started During Heart Failure Hospitalisation: DAPA ACT HF-TIMI 68
DAPA ACT HF-TIMI 68 tested in-hospital initiation of dapagliflozin 10 mg daily in 2,401 patients hospitalised for heart failure.
Remote Monitoring Studies Need to Describe the Clinical Workflow
This review assessed how non-invasive remote patient monitoring studies in heart failure reported their clinical workflows.
Virtual Visits in Heart Failure: Mapping Use Before Judging Impact
This retrospective cohort study described the frequency and predictors of virtual versus in-person visits for people with heart failure with reduced ejection fraction within a large health system.
Neighbourhood Deprivation and Heart Failure Outcomes: A Cohort Study
Using electronic health records from 42,279 adults hospitalised with heart failure, this study examined whether neighbourhood deprivation helped explain racial differences in one-year readmission or all-cause mortality.